<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2105</journal-id><journal-id journal-id-type="pmc-domain">cancers</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10046836</article-id><article-id pub-id-type="pmcid-ver">PMC10046836.1</article-id><article-id pub-id-type="pmcaid">10046836</article-id><article-id pub-id-type="pmcaiid">10046836</article-id><article-id pub-id-type="pmid">36980749</article-id><article-id pub-id-type="doi">10.3390/cancers15061863</article-id><article-id pub-id-type="publisher-id">cancers-15-01863</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012&#8211;2018: A Retrospective, Population-Based Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8705-7581</contrib-id><name name-style="western"><surname>White</surname><given-names initials="BE">Benjamin E.</given-names></name><xref rid="af1-cancers-15-01863" ref-type="aff">1</xref><xref rid="c1-cancers-15-01863" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5640-8425</contrib-id><name name-style="western"><surname>Russell</surname><given-names initials="B">Beth</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-cancers-15-01863" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9530-6448</contrib-id><name name-style="western"><surname>Remmers</surname><given-names initials="S">Sebastiaan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af3-cancers-15-01863" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7619-461X</contrib-id><name name-style="western"><surname>Rous</surname><given-names initials="B">Brian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-cancers-15-01863" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chandrakumaran</surname><given-names initials="K">Kandiah</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-cancers-15-01863" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wong</surname><given-names initials="KF">Kwok F.</given-names></name><xref rid="af4-cancers-15-01863" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van Hemelrijck</surname><given-names initials="M">Mieke</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-cancers-15-01863" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Srirajaskanthan</surname><given-names initials="R">Rajaventhan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af5-cancers-15-01863" ref-type="aff">5</xref><xref rid="fn1-cancers-15-01863" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramage</surname><given-names initials="JK">John K.</given-names></name><xref rid="af1-cancers-15-01863" ref-type="aff">1</xref><xref rid="fn1-cancers-15-01863" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Sharma</surname><given-names initials="R">Rohini</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cancers-15-01863"><label>1</label>Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke RG24 9NA, UK</aff><aff id="af2-cancers-15-01863"><label>2</label>Translational Oncology and Urology Research, School of Cancer &amp; Pharmaceutical Sciences, King&#8217;s College London, London WC2R 2LS, UK</aff><aff id="af3-cancers-15-01863"><label>3</label>Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands</aff><aff id="af4-cancers-15-01863"><label>4</label>NHS Digital, 7 and 8 Wellington Place, Leeds LS1 4AP, UK</aff><aff id="af5-cancers-15-01863"><label>5</label>King&#8217;s Health Partners ENETS Centre of Excellence, King&#8217;s College Hospital, London SE5 9RS, UK</aff><author-notes><corresp id="c1-cancers-15-01863"><label>*</label>Correspondence: <email>benjamin.white7@nhs.net</email>; Tel.: +44-1256-473202</corresp><fn id="fn1-cancers-15-01863"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>15</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">432181</issue-id><elocation-id>1863</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2022</year></date><date date-type="rev-recd"><day>05</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-30 07:10:11.133"><day>30</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cancers-15-01863.pdf"/><abstract><sec><title>Simple Summary</title><p>We conducted a retrospective, population-based study comparing overall survival (OS) between males and females with neuroendocrine neoplasia (NEN). In total, 14,834 cases of NEN recorded in England&#8217;s National Cancer Registry and Analysis Service (NCRAS)), were analysed. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Females displayed increased survival irrespective of the stage, morphology or level of deprivation, which was statistically significant in NEN of the lung, pancreas, rectum and stomach (<italic toggle="yes">p</italic> &lt; 0.001). Stage of tumour mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. Females diagnosed with NEN tend to survive longer than males, and stage at presentation only accounts for part of this effect. Future research in NEN, as well as prognostication and treatment, should consider sex as an important factor.</p></sec><sec><title>Abstract</title><p>Pre-clinical studies have suggested sex hormone signalling pathways may influence tumorigenesis in neuroendocrine neoplasia (NEN). We conducted a retrospective, population-based study to compare overall survival (OS) between males and females with NEN. A total of 14,834 cases of NEN diagnosed between 2012 and 2018, recorded in England&#8217;s National Cancer Registry and Analysis Service (NCRAS), were analysed. The primary outcome was OS with 5 years maximum follow-up. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Appendiceal, pulmonary and early-stage NEN were most commonly diagnosed in females; stomach, pancreatic, small intestinal, colonic, rectal and later-stage NEN were more often diagnosed in males. Females displayed increased survival irrespective of the stage, morphology or level of deprivation. On average, they survived 3.62 (95% CI 1.73&#8211;5.90) to 10.26 (6.6&#8211;14.45) months longer than males; this was statistically significant in NEN of the lung, pancreas, rectum and stomach (<italic toggle="yes">p</italic> &lt; 0.001). The stage mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. The reasons underlying these differences are not yet understood. Overall, females diagnosed with NEN tend to survive longer than males, and the stage at presentation only partially explains this. Future research, as well as prognostication and treatment, should consider sex as an important factor.</p></sec></abstract><kwd-group><kwd>neuroendocrine tumour</kwd><kwd>neuroendocrine tumour</kwd><kwd>neuroendocrine neoplasia</kwd><kwd>carcinoid</kwd><kwd>epidemiology</kwd><kwd>survival</kwd><kwd>incidence</kwd><kwd>predictors of survival</kwd></kwd-group><funding-group><award-group><funding-source>Neuroendocrine Cancer UK</funding-source><award-id>&#163;10,000</award-id></award-group><award-group><funding-source>Hampshire Hospitals NHS Foundation Trust and the National Institute for Health Research</funding-source></award-group><funding-statement>The data were extracted, processed and securely transferred by NCRAS using a grant of &#163;10,000 from Neuroendocrine Cancer UK. B.E.W.&#8217;s salary was funded jointly by Hampshire Hospitals NHS Foundation Trust and the National Institute for Health Research.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-15-01863"><title>1. Introduction</title><p>Neuroendocrine neoplasia (NEN) are tumours arising from neuroendocrine cells; they share the traits of both nervous and endocrine cells and can release hormones in response to neuronal stimuli. NEN can be classified as well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinoma (NEC), which include large and small cell differentiation. Although NEN can occur anywhere in the body, the majority arise in the gastrointestinal tract and lungs [<xref rid="B1-cancers-15-01863" ref-type="bibr">1</xref>,<xref rid="B2-cancers-15-01863" ref-type="bibr">2</xref>]. The symptomatology can be highly variable and is dependent on the tumour burden and hormone-secreting capacity [<xref rid="B3-cancers-15-01863" ref-type="bibr">3</xref>].</p><p>The incidence of NEN is increasing globally [<xref rid="B4-cancers-15-01863" ref-type="bibr">4</xref>]; theories to explain this include increased clinical awareness, more widespread availability of imaging techniques and endoscopy, and a possible &#8216;real&#8217; increase. Risk factors for developing NEN include a family history of cancer, type 2 diabetes, obesity, cigarette smoking and alcohol intake. These findings are from retrospective case&#8211;control studies; high-quality prospective trials to identify risk factors have not yet been performed in NEN [<xref rid="B5-cancers-15-01863" ref-type="bibr">5</xref>,<xref rid="B6-cancers-15-01863" ref-type="bibr">6</xref>,<xref rid="B7-cancers-15-01863" ref-type="bibr">7</xref>]. </p><p>Survival at each NEN tumour site has improved in England over the last 25 years. This is likely due to a combination of increased detection of low-stage tumours resulting in &#8216;stage shift&#8217; and the effect of treatment advances [<xref rid="B8-cancers-15-01863" ref-type="bibr">8</xref>]. The predictors of survival at diagnosis of NEN identified so far are age, sex, organ site, stage, grade, deprivation (also known as socio-economic status) and marital status. As in other solid organ cancers, there are survival differences by sex in NEN. Population-based studies from North America that include large numbers of tumours have shown males to have statistically significant worse overall survival (OS), with HRs up to 1.26&#8211;1.27 for males compared to females [<xref rid="B9-cancers-15-01863" ref-type="bibr">9</xref>,<xref rid="B10-cancers-15-01863" ref-type="bibr">10</xref>]. Large cohort analyses from other population-based databases in England, Canada, Australia, Norway, Taiwan and others also demonstrated statistically significant worse OS in males in multivariable analysis [<xref rid="B11-cancers-15-01863" ref-type="bibr">11</xref>,<xref rid="B12-cancers-15-01863" ref-type="bibr">12</xref>,<xref rid="B13-cancers-15-01863" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01863" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01863" ref-type="bibr">15</xref>].</p><p>Overall, sex plays an important role in survival from solid organ cancers [<xref rid="B16-cancers-15-01863" ref-type="bibr">16</xref>]. Sex is a key modifier of pathophysiology via genetic, epigenetic and hormonal regulation. A different biological sex environment is created by genetic heterogeneity at the molecular level. Evidence shows that sex hormones affect cellular responses by modifying DNA expression, which in turn leads to different cell surface receptor expression [<xref rid="B17-cancers-15-01863" ref-type="bibr">17</xref>]. Not only does this result in differing predispositions to and the manifestation of malignancy but it also affects the response to cancer therapy. Societal factors also play a role by influencing behaviours such as diet, smoking and physical activity, which in turn can influence health outcomes. Perceived gender also affects how a patient is treated both by society and clinicians [<xref rid="B16-cancers-15-01863" ref-type="bibr">16</xref>]. </p><p>Male predominance in solid organ cancers that affect both sexes has been observed worldwide [<xref rid="B18-cancers-15-01863" ref-type="bibr">18</xref>]. Males are known to have greater exposure to risk factors, such as occupational, alcohol intake and smoking risk factors [<xref rid="B19-cancers-15-01863" ref-type="bibr">19</xref>]. Survival is shorter for males across multiple solid organ cancer types [<xref rid="B20-cancers-15-01863" ref-type="bibr">20</xref>]. As described above, these differences may be explained by sex-specific biology having effects on tumorigenesis, the stimulatory effects of androgens in male individuals and the protective effects of oestrogens in females seen in non-reproductive cancers [<xref rid="B21-cancers-15-01863" ref-type="bibr">21</xref>], in addition to the influence of the societal, cultural or behavioural effect of gender roles.</p><p>Several pre-clinical studies have shown that the expression of oestrogen and progesterone receptors is associated with favourable outcomes amongst patients with gastroenteropancreatic NEN (GEP-NEN). Pancreatic NEN (pNEN) with higher oestrogen receptor-&#946; expression are associated with a more favourable prognosis [<xref rid="B22-cancers-15-01863" ref-type="bibr">22</xref>]. Females, especially those who are pre-menopausal, have a lower risk of mesenteric metastasis in small intestinal NEN (SI-NEN). SI-NEN have increased oestrogen and androgen receptor expression compared to normal tissue, suggesting that sex hormone signalling pathways may modulate metastatic potential [<xref rid="B23-cancers-15-01863" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01863" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01863" ref-type="bibr">25</xref>]. Immunohistochemical assessment of progesterone receptor (PR) status may help to identify GEP-NEN with the potential for more aggressive behaviour [<xref rid="B26-cancers-15-01863" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01863" ref-type="bibr">27</xref>]. Histological differences between males and females in lung carcinoids have also been identified [<xref rid="B28-cancers-15-01863" ref-type="bibr">28</xref>]. A clinical trial is investigating the effect of tamoxifen in well-differentiated NEN based on oestrogen and progesterone receptors being expressed in around 20% of NEN [<xref rid="B29-cancers-15-01863" ref-type="bibr">29</xref>].</p><p>We aimed to use restricted mean survival time (RMST) and mediation analysis to compare survival by sex in NEN and examine the influence of the stage on survival outcomes. To our knowledge, there are no other studies that have yet analysed sex differences in NEN in this way.</p></sec><sec sec-type="methods" id="sec2-cancers-15-01863"><title>2. Methods</title><sec id="sec2dot1-cancers-15-01863"><title>2.1. Data Source</title><p>This work utilised data from the National Cancer Registry and Analysis Service (NCRAS) of England, which captures over 99% of tumours recorded in England&#8217;s National Health Service [<xref rid="B30-cancers-15-01863" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01863" ref-type="bibr">31</xref>]. The data were collected for individuals aged 16 and above who had been diagnosed with NEN between 2012 and 2018. The NCRAS database is updated as histopathological classification systems change, which presents a challenge in a rapidly evolving field such as NEN. Stage is recorded by NCRAS according to the European Neuroendocrine Tumor Society (ENETS) system for foregut [<xref rid="B32-cancers-15-01863" ref-type="bibr">32</xref>] and mid- and hindgut [<xref rid="B33-cancers-15-01863" ref-type="bibr">33</xref>] tumours and uses the Union for International Cancer Control tumour, node and metastasis system (UICC TNM) [<xref rid="B34-cancers-15-01863" ref-type="bibr">34</xref>] for other sites. </p></sec><sec id="sec2dot2-cancers-15-01863"><title>2.2. NEN Classification and Analytic Process</title><p>NEN occurring at all anatomical sites between C00 and C80 and malignant neoplasms of all sites (excluding haematological malignancy), according to the 10th edition of the WHO International Classification of Disease (ICD-10) were included. The morphology codes included 8013 (excluding lung [C34 and C78]), 8041&#8211;8045 (excluding lung), 8150&#8211;8158, 8240&#8211;8247, 8249 and 9091, according to the WHO International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) [<xref rid="B35-cancers-15-01863" ref-type="bibr">35</xref>] in line with previously published work on NEN based on NCRAS data [<xref rid="B13-cancers-15-01863" ref-type="bibr">13</xref>]. Large cell neuroendocrine and small cell carcinomas of the lung were excluded to enable a comparison with previous analyses and because the high incidence in this organ due to smoking would skew the results. Goblet cell adenocarcinomas (GCA) (ICD-O-3: 8243) were excluded from the dataset in view of their reclassification as non-NEN [<xref rid="B36-cancers-15-01863" ref-type="bibr">36</xref>]. Duplicate tumours and tumours recorded as &#8216;death certificate only&#8217;, which made up less than 0.1% of the tumours, were excluded [<xref rid="B37-cancers-15-01863" ref-type="bibr">37</xref>,<xref rid="B38-cancers-15-01863" ref-type="bibr">38</xref>].</p><p>Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) (formerly termed mixed adenoneuroendocrine carcinomas (MANEC)) and Merkel cell tumours were excluded. Only tumours diagnosed from 2012 onwards were included in the main survival analysis due to markedly improved coding and classification in recent years; unclassified stage tumours (25.6%) were excluded. It was decided that imputing missing data was not desirable due to a risk of bias in the resulting dataset [<xref rid="B39-cancers-15-01863" ref-type="bibr">39</xref>].</p><p>Site groups were created from histological codes. The main sites were defined as the appendix, caecum, colon, lung, pancreas, rectum, small intestine or stomach, in line with other series [<xref rid="B40-cancers-15-01863" ref-type="bibr">40</xref>]. Tumours with a primary site not registered as one of these &#8216;main&#8217; primaries were excluded in order to clearly define the cohort and avoid inaccuracy in analysing the likely metastatic sites.</p><p>We, therefore, grouped the NEN morphologically, either as well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC), similar to other recently published work [<xref rid="B41-cancers-15-01863" ref-type="bibr">41</xref>]. The tumours classified as NET included carcinoids of typical, atypical, tubular and other well-differentiated neoplasms such as insulinoma and glucagonoma. The NEC included all the carcinomas and tumours with large and small cell neuroendocrine differentiation. Although all tumours have a histopathological classification, the Ki-67 index was not yet available on the NCRAS database at the time of the data transfer. </p><p>The available variables suitable to be included in the analysis were site, age, sex, index of multiple deprivation (IMD), morphology and stage. The IMD is a measure of relative deprivation for small areas of England (lower layer super output areas, LSOA) and is composed of seven domains with relative weights: income (22.5%), employment (22.5), education (13.5%), health (13.5%), crime (9.3%), housing (9.3%) and environment (9.3%). </p></sec><sec id="sec2dot3-cancers-15-01863"><title>2.3. Statistical Analytic Approach</title><p>The categorical variables were presented as percentages; the continuous variables were reported as the median and interquartile range (IQR). The primary endpoint was OS, calculated from the date of diagnosis and censored on 31 March 2020 and calculated using the Kaplan-Meier estimator with a maximum of 5 years follow-up. The 95% confidence interval (95% CI) was specified for all the results. All the variables were included in the multivariable analysis except for ethnicity. Ethnicity was excluded due to skewed data.</p><p>Cox regression multivariable analysis included sex, morphology, age group, stage, site and deprivation. Of these, sex and deprivation met proportional hazards assumptions. The other variables did not strictly meet proportional hazards assumptions and were therefore included in the final multivariable model as covariates with a time-varying effect (TVC). There was no multicollinearity between the variables. The accelerated failure time (AFT) models were tested for significance against the null models (Cox) using a likelihood ratio test (<italic toggle="yes">p</italic> &lt; 0.001). We aimed to use age-adjusted restricted mean survival time (RMST) as a method to compare survival between the sexes. RMST is defined as the area under the survival curve up to a specific time point and can overcome some of the limitations of proportional hazard modelling [<xref rid="B42-cancers-15-01863" ref-type="bibr">42</xref>]. </p><p>The stage at presentation might explain some of the survival differences observed in NEN between males and females. Early-stage appendiceal and lung NEN, for example, occur more frequently in females, whilst late-stage pancreatic and stomach NEN occur more frequently in males [<xref rid="B8-cancers-15-01863" ref-type="bibr">8</xref>]. Mediation analysis can be used to further study the relationship between sex and survival and how this is influenced by the stage [<xref rid="B43-cancers-15-01863" ref-type="bibr">43</xref>]. Mediation analysis looks at how the relationship between an exposure (e.g., sex) and an outcome (e.g., survival) might be mediated by another variable (e.g., stage) whilst adjusting for other confounding factors (e.g., morphology, deprivation). </p><p>RMST and age-adjusted RMST were calculated using the <italic toggle="yes">strmst2</italic> command in STATA. Mediation analysis was performed using the <italic toggle="yes">med4way</italic> command in STATA. For the mediation analysis, as mediators in med4way can be either continuous or dichotomous, stages I and II were classed as &#8216;early&#8217; stage and stages III and IV were classed as &#8216;late&#8217; stage. The statistical analyses and plots were performed using STATA/MP 16.0 (College Station, TX, USA: StataCorp LLC) and R.</p></sec></sec><sec sec-type="results" id="sec3-cancers-15-01863"><title>3. Results</title><p>In total, 14,834 tumours recorded on the NCRAS database between 2012 and 2018 were eligible for analysis. The largest proportion of tumours occurred in the 65&#8211;74 age group, with a median age for the cohort of 65 (IQR 53-73) (<xref rid="cancers-15-01863-t001" ref-type="table">Table 1</xref>). Closely matching the ethnic mix of England, the most frequent ethnicity was White (89%), followed by Asian (2.9%) and Black (2.3%).</p><p>The most common primary site was the lung (4661; 31.4% of tumours), followed by the small intestine (3201; 21.6%), pancreas (2183; 14.7%) and appendix (2146; 14.5%). Most tumours in the cohort were either stage I (5040; 34.0% of tumours) or stage IV (5121; 34.5%), with stages II and III being less frequent. There were 11,080 NET (74.7%) and 3754 NEC (25.3%). The tumours were spread relatively evenly across deprivation quintiles (20.5% to 18.3%) (<xref rid="cancers-15-01863-t001" ref-type="table">Table 1</xref>).</p><p>Overall, there were slightly more females than males diagnosed with NEN (51.5% female vs. 48.5% male) (<xref rid="cancers-15-01863-t002" ref-type="table">Table 2</xref>). The median age was similar in males and females (65.5 vs. 65). The youngest age group displayed female predominance (60.9%), but this disparity ceased above age 54 where the tumours became more evenly distributed. </p><p>The appendix and lung sites were predominantly diagnosed in females (61.3% and 60.2% female), but stomach, pancreas, small intestine, colon and rectal NEN were most frequently diagnosed in males (56.3&#8211;61.9%). Stage I and II tumours showed a female preponderance (60.4% and 53.6% female). However, there were more stage III and IV tumours diagnosed in males (53.4% and 55.6% male). The sex distribution was relatively equal across all the deprivation quintiles. There were more NET diagnosed in females (54.0% female). However, the opposite was true in NEC, where 56.0% of the diagnoses occurred in males.</p><p>As expected, increasing age was associated with progressively increased hazard ratios (HR); compared to the &lt;30 age group, the HR was 4.41 (95% CI 2.88&#8211;6.74) for the 30&#8211;54 age group, 5.35 (3.50&#8211;8.18) for the 55&#8211;65 age group, 6.13 (4.01&#8211;9.37) for the 65&#8211;74 age group and 7.72 (5.06&#8211;11.80) for those over 75. The rectum 1.27 (1.15&#8211;1.41) and stomach 1.26 (1.14&#8211;1.33) had the highest HRs of any of the main sites when compared to the appendix. Increasing stage was associated with increasing hazard, and the same pattern was observed with increasing deprivation quintile. A NEC was associated with a significantly increased HR compared to a NET (HR 1.29 (1.25&#8211;1.33)) (<xref rid="cancers-15-01863-t003" ref-type="table">Table 3</xref>).</p><p>The age-adjusted 5-year RMST (<xref rid="cancers-15-01863-t003" ref-type="table">Table 3</xref>) of the main sites showed that females displayed a survival advantage ranging from 3.62 (95% CI 1.73 to 5.90) to 10.26 (6.6 to 14.45) months. The exception was colonic NEN, which showed a male survival advantage, but this was not statistically significant. The sites where females showed a statistically significant improved survival were the lung, pancreas, rectum and stomach (all <italic toggle="yes">p</italic> &lt; 0.001). Females had an increased survival at all tumour stages: 1.2 months (0.48 to 1.92) for stage I, 3.24 months (1.76 to 4.72) for stage II, 2.23 months (0.58 to 3.89) for stage III and 3.19 months (1.84 to 4.54) for stage IV. All these results were statistically significant (<italic toggle="yes">p</italic> &lt; 0.001 except Stage III <italic toggle="yes">p</italic> = 0.008). Compared to the males, females survived longer when diagnosed with both morphological groups of NET or NEC, with an HR of 2.44 (1.74 to 3.13) and 4.92 (3.46 to 6.37) months, respectively (<italic toggle="yes">p</italic> &lt; 0.001). Similarly, females had a longer survival in all the deprivation quintiles (4.45 to 5.14 months, <italic toggle="yes">p</italic> &lt; 0.001).</p><p>Four-way decomposition mediation analysis of the four main primary sites found females to have a statistically significant survival advantage. <xref rid="cancers-15-01863-t004" ref-type="table">Table 4</xref> shows that females are less likely to be diagnosed at a later stage than males. Consistent with the age-adjusted RMST findings, females survived longer than males in all four sites according to the model for the outcome at each site. The stage mediated improved survival in females to a significant extent (37%) in stomach NEN and moderately (20%) in lung and pancreas NEN. The stage did not play a role (4%) in mediating survival in rectal NEN (<xref rid="cancers-15-01863-f001" ref-type="fig">Figure 1</xref>). </p></sec><sec sec-type="discussion" id="sec4-cancers-15-01863"><title>4. Discussion</title><p>This study demonstrates that females diagnosed with neuroendocrine neoplasia display a survival advantage compared to males. Sex is a statistically significant predictor of survival in multivariable analysis [<xref rid="B8-cancers-15-01863" ref-type="bibr">8</xref>]. The survival advantage for females remained statistically significant when examining the subgroups (<xref rid="cancers-15-01863-t003" ref-type="table">Table 3</xref>). When examining the primary sites, those sites with a statistically significant increase in overall survival in females are the lung, pancreas, rectum and stomach. </p><p>Mediation analysis suggested that the stage is responsible for the survival advantage seen in females to different extents depending on the primary site. The stage (early or late) at diagnosis appears to explain the survival advantage in stomach NEN to a large extent, in lung and pancreas NEN moderately and not at all in rectal NEN. The reasons underlying these differences are not yet understood. The stage is, therefore, an important intermediate (i.e., a mediator) on the pathway of the association between sex and survival and might help direct investigation of underlying causes. </p><p>Although we have demonstrated that the stage partially explains differential survival according to sex in NEN, it is not clear why females tend to be diagnosed earlier than males with lung NEN, whilst the reverse is true for pancreatic and stomach NEN. Females were also observed to survive longer than males, even when diagnosed with the same stage and morphological type of NEN. Suggested explanations put forward for this in the past include biological reasons (including genetic, hormonal and other factors) [<xref rid="B17-cancers-15-01863" ref-type="bibr">17</xref>,<xref rid="B18-cancers-15-01863" ref-type="bibr">18</xref>] and environmental reasons (including behavioural, societal and cultural factors) [<xref rid="B16-cancers-15-01863" ref-type="bibr">16</xref>]. Other country or health system-specific factors may also play a role, such as screening programmes for cancer or prominent public health campaigns. </p><p>As described previously, there is an increasing body of pre-clinical research seeking to explain the sex difference in NEN. The expression of oestrogen and progesterone receptors, or sex hormone signalling pathways, may play a role in the differing biology between the sexes and tumorigenesis [<xref rid="B22-cancers-15-01863" ref-type="bibr">22</xref>,<xref rid="B23-cancers-15-01863" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01863" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01863" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01863" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01863" ref-type="bibr">27</xref>].</p><p>We suggest that future research could try to explain why females are presenting with earlier-stage NEN of the lung and males are presenting with later-stage NEN of the pancreas and stomach. This could be examined by looking at the mode of presentation or diagnosis, not sufficiently complete for us to analyse. The linkage of general practice records at the patient level, which would enable a richer analysis of risk factors such as smoking and obesity, might also help to explain the difference [<xref rid="B44-cancers-15-01863" ref-type="bibr">44</xref>].</p><p>At presentation, it would be difficult to distinguish late-stage NEN, which have been slow-growing and undiscovered but may have transformed recently from aggressive ones, which have only been present for a short time. NEN could have had differing durations of exposure to an oncogenic microenvironment, which might mean a greater impact of sex differences, for example, the duration of exposure to sex hormones. To investigate this, a study model could be devised to predict the risk of the development of NEN compared to a background rate in the population before and after menopause. Since NEN are thought to be slow-growing tumours, commonly with the tumour being present both before and after menopause, this study design may be complex [<xref rid="B25-cancers-15-01863" ref-type="bibr">25</xref>].</p><p>The use of Ki-67 in future studies would be beneficial, allowing for the mitotic index to be taken into account when analysing the differences in survival. Ki-67 has been recorded in the NCRAS database from 2020 onwards, reflecting how histological classification has developed over time, representing a good opportunity for further investigation [<xref rid="B45-cancers-15-01863" ref-type="bibr">45</xref>]. Another model to further characterise how sex influences survival in NEN might be to retrospectively examine the differences between patients with a co-diagnosis of NEN and prostate cancer, having or not having antiandrogen therapy, as the role of androgen deprivation in survival from these tumours is unclear [<xref rid="B46-cancers-15-01863" ref-type="bibr">46</xref>].</p><p>The limitations of this retrospective, population-based study include a historic lack of quality recorded data before 2012, particularly regarding the stage and morphology, meaning it was not possible to accurately compare these findings to earlier time periods. We had to rely on morphology to characterise the tumours, without a grade or Ki-67, again due to the incompleteness of the data. It was not possible to accurately analyse the diagnostic imaging pathways, chemotherapy treatments or health system routes to diagnosis due to the incompleteness of the data. However, this is improving over time as the NCRAS database becomes more complete.</p></sec><sec sec-type="conclusions" id="sec5-cancers-15-01863"><title>5. Conclusions</title><p>We have demonstrated that females diagnosed with NEN tend to survive longer than males. The stage at presentation is only partially responsible for this difference and does not explain the underlying causes. It is not possible in this analysis to demonstrate causality with respect to sex hormones or other sex differences, such as treatment histories, which may be influencing this relationship. More research is needed to understand how sex affects presentation, disease progression and treatment response in NEN. Our research suggests that prognostication and treatment should take sex and gender into account. We suggest that future trials in NEN should consider and report on sex and gender throughout the research process.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank NHS Digital and The National Cancer Registration and Analysis Service for providing us with the registry data for analysis. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to thank Hampshire Hospitals NHS Foundation Trust for sponsoring the study and Neuroendocrine Cancer UK for providing funding.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-cancers-15-01863"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/cancers15061863/s1">https://www.mdpi.com/article/10.3390/cancers15061863/s1</uri>, Table S1. Sex differential of NEN by main organ primary, stage and morphology. n, number of tumours; NET, neuroendocrine tumour; NEC, neuroendocrine carcinoma.</p><supplementary-material id="cancers-15-01863-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cancers-15-01863-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>B.E.W. is the author of the original and final draft. All the authors contributed to reviewing and editing the drafts equally. Below are the details of the authors&#8217; specific contributions. B.E.W.: Conceptualisation; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Validation; Visualisation. B.R. (Beth Russell): Formal analysis; Investigation; Methodology; Validation. S.R.: Formal analysis; Methodology; Validation; Visualisation. B.R. (Brian Rous): Data curation; Investigation; Methodology; Supervision; Validation; Visualisation. K.C.: Data curation; Formal analysis; Investigation; Methodology; Supervision; Validation. K.F.W.: Data curation; Formal analysis; Investigation; Methodology; Supervision; Validation. M.V.H.: Formal analysis; Investigation; Methodology; Supervision; Validation; Visualisation. R.S.: Conceptualisation; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Visualisation. J.K.R.: Conceptualisation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualisation. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Ethics committee approval for study was from NHS Health Research Authority, REC reference: 20/NW/0342. IRAS project ID: 284875. Sponsor: Hampshire Hospitals NHS Foundation Trust.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets presented in this article are not readily available as NCRAS data is restricted by law.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-15-01863"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cives</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pelle&#8217;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strosberg</surname><given-names>J.</given-names></name></person-group><article-title>Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>3655</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9113655</pub-id><pub-id pub-id-type="pmid">33202931</pub-id><pub-id pub-id-type="pmcid">PMC7696369</pub-id></element-citation></ref><ref id="B2-cancers-15-01863"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caplin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Baudin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferolla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Filosso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garcia-Yuste</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pelosi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Perren</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>R.E.</given-names></name><etal/></person-group><article-title>Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids</article-title><source>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.</source><year>2015</year><volume>26</volume><fpage>1604</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv041</pub-id><pub-id pub-id-type="pmid">25646366</pub-id></element-citation></ref><ref id="B3-cancers-15-01863"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Srirajaskanthan</surname><given-names>R.</given-names></name></person-group><article-title>Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome</article-title><source>J. Oncol.</source><year>2020</year><volume>2020</volume><fpage>8341426</fpage><pub-id pub-id-type="doi">10.1155/2020/8341426</pub-id><pub-id pub-id-type="pmid">32322270</pub-id><pub-id pub-id-type="pmcid">PMC7160731</pub-id></element-citation></ref><ref id="B4-cancers-15-01863"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dasari</surname><given-names>A.</given-names></name></person-group><article-title>Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?</article-title><source>Curr. Oncol. Rep.</source><year>2021</year><volume>23</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1007/s11912-021-01029-7</pub-id><pub-id pub-id-type="pmid">33719003</pub-id><pub-id pub-id-type="pmcid">PMC8118193</pub-id></element-citation></ref><ref id="B5-cancers-15-01863"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dagohoy</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.C.</given-names></name></person-group><article-title>Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study</article-title><source>Int. J. Cancer</source><year>2008</year><volume>123</volume><fpage>867</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1002/ijc.23529</pub-id><pub-id pub-id-type="pmid">18491401</pub-id></element-citation></ref><ref id="B6-cancers-15-01863"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haugvik</surname><given-names>S.-P.</given-names></name><name name-style="western"><surname>Hedenstr&#246;m</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kors&#230;th</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valente</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siuka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maisonneuve</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gladhaug</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Lindkvist</surname><given-names>B.</given-names></name><name name-style="western"><surname>Capurso</surname><given-names>G.</given-names></name></person-group><article-title>Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis</article-title><source>Neuroendocrinology</source><year>2015</year><volume>101</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1159/000375164</pub-id><pub-id pub-id-type="pmid">25613442</pub-id></element-citation></ref><ref id="B7-cancers-15-01863"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feola</surname><given-names>T.</given-names></name><name name-style="western"><surname>Puliani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sesti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Modica</surname><given-names>R.</given-names></name><name name-style="western"><surname>Centello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Minotta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cannavale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Meglio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Vito</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lauretta</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): A three-centric case&#8211;control study</article-title><source>J. Endocrinol. Investig.</source><year>2022</year><volume>45</volume><fpage>849</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1007/s40618-021-01715-0</pub-id><pub-id pub-id-type="pmid">35040099</pub-id></element-citation></ref><ref id="B8-cancers-15-01863"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Rous</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chandrakumaran</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Hemelrijck</surname><given-names>M.</given-names></name><name name-style="western"><surname>George</surname><given-names>G.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Srirajaskanthan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramage</surname><given-names>J.K.</given-names></name></person-group><article-title>Incidence and survival of neuroendo-crine neoplasia in England 1995&#8211;2018: A retrospective, population-based study</article-title><source>Lancet Reg. Health-Eur.</source><year>2022</year><volume>23</volume><fpage>100510</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2022.100510</pub-id><pub-id pub-id-type="pmid">36176500</pub-id><pub-id pub-id-type="pmcid">PMC9513765</pub-id></element-citation></ref><ref id="B9-cancers-15-01863"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Prognosis of patients with neuroendocrine tumor: A SEER database analysis</article-title><source>Cancer Manag. Res.</source><year>2018</year><volume>10</volume><fpage>5629</fpage><lpage>5638</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S174907</pub-id><pub-id pub-id-type="pmid">30519109</pub-id><pub-id pub-id-type="pmcid">PMC6239108</pub-id></element-citation></ref><ref id="B10-cancers-15-01863"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Rahman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>N.</given-names></name></person-group><article-title>Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study</article-title><source>Pancreas</source><year>2021</year><volume>50</volume><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000001821</pub-id><pub-id pub-id-type="pmid">34016894</pub-id></element-citation></ref><ref id="B11-cancers-15-01863"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Law</surname><given-names>C.H.L.</given-names></name><name name-style="western"><surname>Cukier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saskin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes</article-title><source>Cancer</source><year>2015</year><volume>121</volume><fpage>589</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1002/cncr.29099</pub-id><pub-id pub-id-type="pmid">25312765</pub-id></element-citation></ref><ref id="B12-cancers-15-01863"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyar Cetinkaya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aagnes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Myklebust</surname><given-names>T.&#197;.</given-names></name><name name-style="western"><surname>Thiis-Evensen</surname><given-names>E.</given-names></name></person-group><article-title>Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study</article-title><source>Int. J. Cancer</source><year>2018</year><volume>142</volume><fpage>1139</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1002/ijc.31137</pub-id><pub-id pub-id-type="pmid">29082524</pub-id></element-citation></ref><ref id="B13-cancers-15-01863"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genus</surname><given-names>T.S.E.</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Srirajaskanthan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rous</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Valle</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>N.</given-names></name><name name-style="western"><surname>Elshafie</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013&#8211;2015</article-title><source>Br. J. Cancer</source><year>2019</year><volume>121</volume><fpage>966</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1038/s41416-019-0606-3</pub-id><pub-id pub-id-type="pmid">31649320</pub-id><pub-id pub-id-type="pmcid">PMC6889414</pub-id></element-citation></ref><ref id="B14-cancers-15-01863"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyld</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>N.</given-names></name><name name-style="western"><surname>Youl</surname><given-names>P.</given-names></name></person-group><article-title>Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia</article-title><source>Cancer Epidemiol.</source><year>2019</year><volume>63</volume><fpage>101598</fpage><pub-id pub-id-type="doi">10.1016/j.canep.2019.101598</pub-id><pub-id pub-id-type="pmid">31539715</pub-id></element-citation></ref><ref id="B15-cancers-15-01863"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.-T.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.-R.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>H.-J.</given-names></name></person-group><article-title>An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>7881</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-86839-2</pub-id><pub-id pub-id-type="pmid">33846396</pub-id><pub-id pub-id-type="pmcid">PMC8041887</pub-id></element-citation></ref><ref id="B16-cancers-15-01863"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauvais-Jarvis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Merz</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Brinton</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Carrero</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>DeMeo</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Epperson</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Govindan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Sex and gender: Modifiers of health, disease, and medicine</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>565</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31561-0</pub-id><pub-id pub-id-type="pmid">32828189</pub-id><pub-id pub-id-type="pmcid">PMC7440877</pub-id></element-citation></ref><ref id="B17-cancers-15-01863"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claessens</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tilley</surname><given-names>W.</given-names></name></person-group><article-title>Androgen signalling and steroid receptor crosstalk in endocrine cancers</article-title><source>Endocr.-Relat. Cancer</source><year>2014</year><volume>21</volume><fpage>E3</fpage><lpage>E5</lpage><pub-id pub-id-type="doi">10.1530/ERC-14-0274</pub-id><pub-id pub-id-type="pmid">25052914</pub-id></element-citation></ref><ref id="B18-cancers-15-01863"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clocchiatti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cora</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dotto</surname><given-names>G.P.</given-names></name></person-group><article-title>Sexual dimorphism in cancer</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.30</pub-id><pub-id pub-id-type="pmid">27079803</pub-id></element-citation></ref><ref id="B19-cancers-15-01863"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCartney</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leyland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Batty</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>K.</given-names></name></person-group><article-title>Contribution of smoking-related and alcohol-related deaths to the gender gap in mortality: Evidence from 30 European countries</article-title><source>Tob. Control.</source><year>2011</year><volume>20</volume><fpage>166</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1136/tc.2010.037929</pub-id><pub-id pub-id-type="pmid">21228431</pub-id><pub-id pub-id-type="pmcid">PMC3045524</pub-id></element-citation></ref><ref id="B20-cancers-15-01863"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oertelt-Prigione</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adjei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cristina</surname><given-names>V.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coukos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dafni</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dotto</surname><given-names>G.-P.</given-names></name><name name-style="western"><surname>Ducreux</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gender medicine and oncology: Report and consensus of an ESMO workshop</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>1914</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz414</pub-id><pub-id pub-id-type="pmid">31613312</pub-id></element-citation></ref><ref id="B21-cancers-15-01863"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name></person-group><article-title>Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma</article-title><source>Oncol. Lett.</source><year>2019</year><volume>17</volume><fpage>4222</fpage><lpage>4228</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.10127</pub-id><pub-id pub-id-type="pmid">30988804</pub-id><pub-id pub-id-type="pmcid">PMC6447942</pub-id></element-citation></ref><ref id="B22-cancers-15-01863"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estrella</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Broaddus</surname><given-names>R.R.</given-names></name></person-group><article-title>Expression of estrogen-induced genes and estrogen receptor &#946; in pancreatic neuroendocrine tumors: Implications for targeted therapy</article-title><source>Pancreas</source><year>2014</year><volume>43</volume><fpage>996</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000000203</pub-id><pub-id pub-id-type="pmid">25058880</pub-id><pub-id pub-id-type="pmcid">PMC4628823</pub-id></element-citation></ref><ref id="B23-cancers-15-01863"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bla&#382;evi&#263;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zandee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Franssen</surname><given-names>G.J.H.</given-names></name><name name-style="western"><surname>Hofland</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Velthuysen</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Hofland</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Feelders</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>De Herder</surname><given-names>W.W.</given-names></name></person-group><article-title>Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours</article-title><source>Endocr.-Relat. Cancer</source><year>2018</year><volume>25</volume><fpage>245</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1530/ERC-17-0282</pub-id><pub-id pub-id-type="pmid">29255095</pub-id></element-citation></ref><ref id="B24-cancers-15-01863"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bla&#382;evi&#263;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brabander</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zandee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hofland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Franssen</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Velthuysen</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Feelders</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Herder</surname><given-names>W.</given-names></name></person-group><article-title>Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>443</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13030443</pub-id><pub-id pub-id-type="pmid">33503893</pub-id><pub-id pub-id-type="pmcid">PMC7865677</pub-id></element-citation></ref><ref id="B25-cancers-15-01863"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bla&#382;evi&#263;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van Velthuysen</surname><given-names>M.-L.F.</given-names></name><name name-style="western"><surname>Hofland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oudijk</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Herder</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Hofland</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Feelders</surname><given-names>R.A.</given-names></name></person-group><article-title>Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2022</year><volume>107</volume><fpage>e1969</fpage><lpage>e1975</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac001</pub-id><pub-id pub-id-type="pmid">34999838</pub-id><pub-id pub-id-type="pmcid">PMC9016466</pub-id></element-citation></ref><ref id="B26-cancers-15-01863"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnason</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sapp</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Drewniak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdolell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rayson</surname><given-names>D.</given-names></name></person-group><article-title>Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors</article-title><source>Neuroendocrinology</source><year>2011</year><volume>93</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1159/000326820</pub-id><pub-id pub-id-type="pmid">21487213</pub-id></element-citation></ref><ref id="B27-cancers-15-01863"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estrella</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Broaddus</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>A.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>A.</given-names></name></person-group><article-title>Progesterone Receptor and PTEN Expression Predict Survival in Patients With Low- and Intermediate-Grade Pancreatic Neuroendocrine Tumors</article-title><source>Arch. Pathol. Lab. Med.</source><year>2014</year><volume>138</volume><fpage>1027</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.5858/arpa.2013-0195-OA</pub-id><pub-id pub-id-type="pmid">25076292</pub-id></element-citation></ref><ref id="B28-cancers-15-01863"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daskalakis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaltsas</surname><given-names>G.</given-names></name><name name-style="western"><surname>&#214;berg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsolakis</surname><given-names>A.V.</given-names></name></person-group><article-title>Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers</article-title><source>Neuroendocrinology</source><year>2018</year><volume>107</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1159/000493944</pub-id><pub-id pub-id-type="pmid">30244255</pub-id></element-citation></ref><ref id="B29-cancers-15-01863"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Felismino</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Jesus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Camandaroba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>N.</given-names></name><name name-style="western"><surname>Donadio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nobrega</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chinen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>HORMONET: Study of tamoxifen in well differentiated neuroendocrine tumours and hormone receptor positive expression</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>v573</fpage><pub-id pub-id-type="doi">10.1093/annonc/mdz256.024</pub-id></element-citation></ref><ref id="B30-cancers-15-01863"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henson</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Elliss-Brookes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coupland</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vernon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rous</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rashbass</surname><given-names>J.</given-names></name></person-group><article-title>Data Resource Profile: National Cancer Registration Dataset in England</article-title><source>Int. J. Epidemiol.</source><year>2020</year><volume>49</volume><fpage>16</fpage><lpage>16h</lpage><pub-id pub-id-type="doi">10.1093/ije/dyz076</pub-id><pub-id pub-id-type="pmid">31120104</pub-id><pub-id pub-id-type="pmcid">PMC7124503</pub-id></element-citation></ref><ref id="B31-cancers-15-01863"><label>31.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>NCIN</collab></person-group><article-title>Collecting and Using Data</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncin.org.uk/collecting_and_using_data/" ext-link-type="uri">http://www.ncin.org.uk/collecting_and_using_data/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-01-24">(accessed on 24 January 2022)</date-in-citation></element-citation></ref><ref id="B32-cancers-15-01863"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rindi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kl&#246;ppel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alhman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Caplin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Couvelard</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Herder</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Erikssson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Falchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Falconi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Komminoth</surname><given-names>P.</given-names></name><etal/></person-group><article-title>TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system</article-title><source>Virchows Arch.</source><year>2006</year><volume>449</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1007/s00428-006-0250-1</pub-id><pub-id pub-id-type="pmid">16967267</pub-id><pub-id pub-id-type="pmcid">PMC1888719</pub-id></element-citation></ref><ref id="B33-cancers-15-01863"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rindi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kl&#246;ppel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Couvelard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Komminoth</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#246;rner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>McNicol</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Perren</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>A.</given-names></name><etal/></person-group><article-title>TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system</article-title><source>Virchows Arch.</source><year>2007</year><volume>451</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1007/s00428-007-0452-1</pub-id><pub-id pub-id-type="pmid">17674042</pub-id></element-citation></ref><ref id="B34-cancers-15-01863"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Brierley</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Gospodarowicz</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Wittekind</surname><given-names>C.</given-names></name></person-group><source>TNM Classification of Malignant Tumours</source><edition>8th ed.</edition><publisher-name>John Wiley &amp; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B35-cancers-15-01863"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>A.</given-names></name><name name-style="western"><surname>Percy</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Sobin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>S.</given-names></name></person-group><source>International Classification of Diseases for Oncology (ICD-O)</source><edition>3rd ed.</edition><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2013</year></element-citation></ref><ref id="B36-cancers-15-01863"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagtegaal</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Odze</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paradis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rugge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schirmacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Washington</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cree</surname><given-names>I.A.</given-names></name><collab>the WHO Classification of Tumours Editorial Board</collab></person-group><article-title>The 2019 WHO classification of tumours of the digestive system</article-title><source>Histopathology</source><year>2020</year><volume>76</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1111/his.13975</pub-id><pub-id pub-id-type="pmid">31433515</pub-id><pub-id pub-id-type="pmcid">PMC7003895</pub-id></element-citation></ref><ref id="B37-cancers-15-01863"><label>37.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NCIN</collab></person-group><article-title>National Cancer Intelligence Network: Cancer Survival in England by Stage</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/347275/Cancer_survival_in_England_by_stage_report_.pdf" ext-link-type="uri">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/347275/Cancer_survival_in_England_by_stage_report_.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-01-24">(accessed on 24 January 2022)</date-in-citation></element-citation></ref><ref id="B38-cancers-15-01863"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berrino</surname><given-names>F.</given-names></name></person-group><article-title>The EUROCARE Study: Strengths, limitations and perspectives of population-based, comparative survival studies</article-title><source>Ann. Oncol.</source><year>2003</year><volume>14</volume><fpage>v9</fpage><lpage>v13</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdg750</pub-id><pub-id pub-id-type="pmid">14684497</pub-id></element-citation></ref><ref id="B39-cancers-15-01863"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayati Rezvan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>J.A.</given-names></name></person-group><article-title>The rise of multiple imputation: A review of the reporting and implementation of the method in medical research Data collection, quality, and reporting</article-title><source>BMC Med. Res. Methodol.</source><year>2015</year><volume>15</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.1186/s12874-015-0022-1</pub-id><pub-id pub-id-type="pmid">25880850</pub-id><pub-id pub-id-type="pmcid">PMC4396150</pub-id></element-citation></ref><ref id="B40-cancers-15-01863"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Halperin</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.C.</given-names></name></person-group><article-title>Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States</article-title><source>JAMA Oncol.</source><year>2017</year><volume>3</volume><fpage>1335</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.0589</pub-id><pub-id pub-id-type="pmid">28448665</pub-id><pub-id pub-id-type="pmcid">PMC5824320</pub-id></element-citation></ref><ref id="B41-cancers-15-01863"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rindi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Abedi-Ardekani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Asa</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Brambilla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Busam</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>De Krijger</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Dietel</surname><given-names>M.</given-names></name><name name-style="western"><surname>El-Naggar</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal</article-title><source>Mod. Pathol.</source><year>2018</year><volume>31</volume><fpage>1770</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1038/s41379-018-0110-y</pub-id><pub-id pub-id-type="pmid">30140036</pub-id><pub-id pub-id-type="pmcid">PMC6265262</pub-id></element-citation></ref><ref id="B42-cancers-15-01863"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>I.</given-names></name></person-group><article-title>Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers</article-title><source>Korean J. Radiol.</source><year>2022</year><volume>23</volume><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.3348/kjr.2022.0061</pub-id><pub-id pub-id-type="pmid">35506526</pub-id><pub-id pub-id-type="pmcid">PMC9081686</pub-id></element-citation></ref><ref id="B43-cancers-15-01863"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Discacciati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bellavia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mazumdar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valeri</surname><given-names>L.</given-names></name></person-group><article-title>Med4way: A Stata command to investigate mediating and interactive mechanisms using the four-way effect decomposition</article-title><source>Int. J. Epidemiol.</source><year>2018</year><volume>48</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy236</pub-id><pub-id pub-id-type="pmid">30452641</pub-id></element-citation></ref><ref id="B44-cancers-15-01863"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padmanabhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carty</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.</given-names></name><name name-style="western"><surname>Strongman</surname><given-names>H.</given-names></name></person-group><article-title>Approach to record linkage of primary care data from Clinical Practice Research Datalink to other health-related patient data: Overview and implications</article-title><source>Eur. J. Epidemiol.</source><year>2019</year><volume>34</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s10654-018-0442-4</pub-id><pub-id pub-id-type="pmid">30219957</pub-id><pub-id pub-id-type="pmcid">PMC6325980</pub-id></element-citation></ref><ref id="B45-cancers-15-01863"><label>45.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Luong</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chakrabarty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.M.</given-names></name></person-group><article-title>Standards and Datasets for Reporting Cancers Dataset for Histopathological Reporting of Neuroendocrine Neoplasms of the Gastroenteropancreatic Tract DRAFT</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acpgbi.org.uk/_userfiles/import/2019/05/Dataset-for-histopathological-reporting-of-neuroendocrine-neoplasms-of-the-gastroenteropancreatic-tract-For-Consultation-002.pdf" ext-link-type="uri">https://www.acpgbi.org.uk/_userfiles/import/2019/05/Dataset-for-histopathological-reporting-of-neuroendocrine-neoplasms-of-the-gastroenteropancreatic-tract-For-Consultation-002.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-11-04">(accessed on 4 November 2022)</date-in-citation></element-citation></ref><ref id="B46-cancers-15-01863"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name></person-group><article-title>ADT with antiandrogens in prostate cancer induces adverse effect of in-creasing resistance, neuroendocrine differentiation and tumor metastasis</article-title><source>Cancer Lett.</source><year>2018</year><volume>439</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.09.020</pub-id><pub-id pub-id-type="pmid">30227222</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cancers-15-01863-f001" orientation="portrait"><label>Figure 1</label><caption><p>Total effect (Time ratio) by site in four-way decomposition mediation analysis. Proportion of the total effect mediated by stage shown as dark red area within bar. Error bars shown for total effect.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancers-15-01863-g001.jpg"/></fig><table-wrap position="float" id="cancers-15-01863-t001" orientation="portrait"><object-id pub-id-type="pii">cancers-15-01863-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographics of 14,834 NEN occurring at main organ primary sites 2012&#8211;2018. IQR, interquartile range; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumour. Sex differential of NEN by main organ primary, stage and morphology see <xref rid="app1-cancers-15-01863" ref-type="app">Supplementary Table S1</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">14,834</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (Median, IQR)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">65 (53&#8211;73)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Age group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#8211;30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">909</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.1%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31&#8211;54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3141</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.2%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55&#8211;64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3117</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4450</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.7%</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ethnicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">425</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.9%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">338</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed race</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">192</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,197</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">618</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2%</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Site</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appendix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2146</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.5%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caecum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">528</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">509</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4661</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2183</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.7%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">948</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small intestine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3201</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.6%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stomach</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.4%</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5040</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.5%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2669</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5121</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.5%</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Morphology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,080</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.7%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NEC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3754</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.3%</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Deprivation quintile</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8212;least deprived</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.5%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3194</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.5%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3148</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.2%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2722</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.3%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8212;most deprived</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2722</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.3%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-15-01863-t002" orientation="portrait"><object-id pub-id-type="pii">cancers-15-01863-t002_Table 2</object-id><label>Table 2</label><caption><p>Demographics of 14,834 NEN by sex differential. IQR, interquartile range; NET, neuroendocrine tumour; NEC, neuroendocrine carcinoma.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="5" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age Group</th><th colspan="6" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Ethnicity</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total<break/>14,834</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median Age (IQR)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#8211;30</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31&#8211;54</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55&#8211;64</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;74</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75+</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed Race</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not Stated</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Male</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7196</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">65.5 <break/>(54&#8211;73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">355</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1447</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1562</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2257</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1575</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">218</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">145</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6389</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">313</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.5%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.7%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.6%</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Female</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7638</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">65 <break/>(51&#8211;73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">554</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1694</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1555</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2193</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1642</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">207</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">193</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6808</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">305</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.5%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.7%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="8" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Site</bold>
</td><td colspan="4" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Stage</bold>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Appendix</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Caecum</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Colon</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Lung</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Pancreas</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rectum</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Small Intestine</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Stomach</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>I</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>II</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>III</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IV</bold>
</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Male</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">831</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">228</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">298</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1854</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1230</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">544</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1804</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">407</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">929</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1425</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2846</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.7%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.5%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.6%</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Female</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1315</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">211</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2807</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">953</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">404</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1397</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">251</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3044</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1075</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1244</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2275</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.5%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.7%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="5" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Deprivation Quintile</bold>
</td><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Morphology</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" colspan="2" align="center" valign="middle" style="border-bottom:solid thin">
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>1&#8212;least deprived</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>2</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>3</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>4</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>5&#8212;most deprived</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>NET</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>NEC</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Male</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1524</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1547</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1488</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1354</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1283</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5093</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.7%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Female</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1524</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1647</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1660</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1368</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1439</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5987</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.7%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-15-01863-t003" orientation="portrait"><object-id pub-id-type="pii">cancers-15-01863-t003_Table 3</object-id><label>Table 3</label><caption><p>Multivariable analysis of survival in the cohort with hazard ratios (HR), and analysis of sex differences in 5-year restricted mean survival time (RMST), stratified by variable. Nb. age not displayed in table due to use of age-adjusted RMST. However, results of age in multivariable analysis are included in text.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Multivariable Survival Analysis</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Analysis of Sex Difference in Survival</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">5-year RMST</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age-Adjusted Female Survival Advantage</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Variable</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR (95%CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Months (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Months (95% CI), <italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Site</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appendix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.64 (4.56&#8211;4.72)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.95 (&#8722;0.18 to 2.10), <italic toggle="yes">p</italic> = 0.098</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.041</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.76 (4.71&#8211;4.82)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caecum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01 (0.9&#8211;1.11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.11 (2.83&#8211;3.39)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.77 (&#8722;1.61 to 7.15), <italic toggle="yes">p</italic> = 0.215</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.30 (3.07&#8211;3.54)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.14 (1.04&#8211;1.25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.22 (1.98&#8211;2.47)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#8722;2.44(&#8722;6.90 to 2.04), <italic toggle="yes">p</italic> = 0.287</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99 (1.71&#8211;2.28)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22 (1.13&#8211;1.31)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.96 (2.86&#8211;3.06)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9.85 (8.40 to 11.30), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.76 (3.69&#8211;3.83)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.18 (1.09&#8211;1.28)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.16 (3.05&#8211;3.28)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.62 (1.73 to 5.90), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.52 (3.39&#8211;3.65)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 (1.15&#8211;1.41)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.24 (3.05&#8211;3.42)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.68 (2.38 to 8.96), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.75 (3.55&#8211;3.94)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small intestine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 (0.87&#8211;1.02)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.01 (3.93&#8211;4.09)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.31 (&#8722;0.16 to 2.75), <italic toggle="yes">p</italic> = 0.081</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.09 (4.00&#8211;4.18)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stomach</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.26 (1.14&#8211;1.33)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.18 (1.97&#8211;2.38)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10.26 (6.6 to 14.45), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.22 (2.95&#8211;3.49)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.66 (4.62&#8211;4.71)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.2 (0.48 to 1.92), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.74 (4.71&#8211;4.78)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.38 (1.29&#8211;1.46)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.60 (4.53&#8211;4.67)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.24 (1.76 to 4.72), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.25 (0.05&#8211;4.35)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.58 (1.49&#8211;1.68)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.86 (3.77&#8211;3.95)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.23 (0.58 to 3.89), <italic toggle="yes">p</italic> = 0.008</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.07 (3.97&#8211;4.16)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.11 (2.01&#8211;2.23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.02 (1.94&#8211;2.10)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.19 (1.84 to 4.54), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.28 (2.19&#8211;2.37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morphology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.20 (4.15&#8211; 4.24)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.44 (1.74 to 3.13), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.43 (4.39&#8211;4.46)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NEC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.29 (1.25&#8211;1.33)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.52 (1.45&#8211;1.60)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.92 (3.46 to 6.37), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94 (1.85&#8211;2.04)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deprivation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8212;least deprived</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.53 (3.43&#8211;3.64)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.14 (3.49 to 6.78), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.02 (3.93&#8211;4.11)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 (1.02&#8211;1.21)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.36 (3.26&#8211;3.46)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.68 (4.00 to 7.36), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.90 (3.81&#8211;3.99)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 (1.02&#8211;1.19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.46 (3.35&#8211;3.56)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.16 (3.48 to 6.84), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91 (3.82&#8211;4.00)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21 (1.11&#8211;1.33)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.34 (3.23&#8211;3.46)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.95 (3.32 to 9.98), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.87 (3.77&#8211;3.97)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8212;most deprived</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32 (1.22&#8211;1.45)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.32 (3.20&#8211;3.43)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.45 (2.58 to 6.31), <italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.68 (3.58&#8211;3.78)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-15-01863-t004" orientation="portrait"><object-id pub-id-type="pii">cancers-15-01863-t004_Table 4</object-id><label>Table 4</label><caption><p>Mediation analysis of the four significant sites of NEN using exposure as sex, outcome as survival and mediator as stage group (early or late). <italic toggle="yes">n</italic>, number of tumours;%F, proportion of females; TR, time ratio; OR, odds ratio; CDE, controlled direct effect; INT, interaction; IE, indirect effect; MED, mediation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Four-Way Decomposition</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Site</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%F</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model for Outcome (TR) (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model for Mediator (OR) (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Effect (TR) (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDE%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INT%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IE%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MED%</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4661</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.43 (1.16&#8211;1.76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61 (0.53&#8211;0.71)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.54 (1.22&#8211;1.86)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;12%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2183</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.70 (1.16&#8211;2.50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.67&#8211;0.97)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.72 (1.13&#8211;2.30)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">170%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;80%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">948</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.91 (0.93&#8211;3.91)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 (0.52&#8211;1.19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94 (0.55&#8211;3.32)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stomach</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.50 (0.88&#8211;2.56)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48 (0.32&#8211;0.73)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.64 (0.82&#8211;2.45)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;24%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37%</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>